Cargando…
Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy
INTRODUCTION: To investigate the validity and reliability of the 32-item Motor Function Measure (MFM32) in individuals with neuromuscular disorders (NMD), including spinal muscular atrophy (SMA), aged 2–5 years, and in non-ambulant individuals with Types 2 or 3 SMA, aged 2–25 years. METHODS: Test–re...
Autores principales: | Trundell, Dylan, Le Scouiller, Stephanie, Gorni, Ksenija, Seabrook, Timothy, Vuillerot, Carole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606363/ https://www.ncbi.nlm.nih.gov/pubmed/32856191 http://dx.doi.org/10.1007/s40120-020-00206-3 |
Ejemplares similares
-
Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy
por: Trundell, Dylan, et al.
Publicado: (2020) -
A Patient-Centered Evaluation of Meaningful Change on the 32-Item Motor Function Measure in Spinal Muscular Atrophy Using Qualitative and Quantitative Data
por: Duong, Tina, et al.
Publicado: (2022) -
Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study
por: Annoussamy, Mélanie, et al.
Publicado: (2020) -
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023) -
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)
por: Oskoui, Maryam, et al.
Publicado: (2023)